Telehealth company Ro has a new spokesperson for its booming GLP-1 business: Serena Williams, the 23-time Grand Slam champion ...

This month’s executive moves in the agency, consultancy, and investor sectors reflect a growing emphasis on strategic ...

After UK Health Secretary Wes Streeting sent a letter to the pharma industry, warning that he will withdraw from negotiations ...

Twin Health has raised another $53 million to fund its 'digital twin' platform, which provides a model of a patient's unique ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Suzanne Aitken, SVP of managed access at Clinigen, ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Ionis has won an FDA green light for an RNA-based hereditary angioedema (HAE) treatment, Dawnzera, that can be ...

Johnson & Johnson has filled in some of the details of its $55 billion investment in US facilities announced earlier this ...

The positive data from the Phase 3 Denali trial showed that NCX 470, a nitric oxide-donating bimatoprost eyedrop formulation, ...

A new treatment regimen for advanced bladder cancer combining MSD's Keytruda with Astellas' Padcev has been given the green ...

Today, the value of this approach is widely recognised even by most pharmaceutical companies, a number of which – including Sanofi, Roche and Genentech, Bayer, and Merck KgaA – have partnered with ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to a price of $499 for those paying for the drugs out of pocket. The ...